• Users Online: 1313
  • Print this page
  • Email this page


 
 
Table of Contents
GUEST EDITORIAL
Year : 2016  |  Volume : 3  |  Issue : 1  |  Page : 8-10

Pretreatment with myo-inositol in patients undergoing gonadotropins multiple follicular stimulation for IVF


Centro di Fisiopatologia della riproduzione, Casa di Cura Villa Mafalda, Via Monte delle Gioie 5 _ ROMA

Date of Web Publication5-Jul-2017

Correspondence Address:
Franco Lisi
Centro di Fisiopatologia della riproduzione, Casa di Cura Villa Mafalda, Via Monte delle Gioie 5 _ ROMA

Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.5530/ami.2016.1.4

Rights and Permissions

How to cite this article:
Lisi F. Pretreatment with myo-inositol in patients undergoing gonadotropins multiple follicular stimulation for IVF. Acta Med Int 2016;3:8-10

How to cite this URL:
Lisi F. Pretreatment with myo-inositol in patients undergoing gonadotropins multiple follicular stimulation for IVF. Acta Med Int [serial online] 2016 [cited 2019 Nov 23];3:8-10. Available from: http://www.actamedicainternational.com/text.asp?2016/3/1/8/209727





Myo-inositol is an isomer of a C6 sugar alcohol that belongs to the vitamin B complex group.[1] Myo-inositol (MI) is one of the nine isomeric forms of inositol present in nature and can be synthesized by the body in the follicular microenvironment; various natural forms of inositol also exist, among which the most studied is the D-chiro-inositol (DCI), which is not synthesized from precursors in the body but obtained from epimerization of Myo Inositol.[2] In stereochemistry, epimer refers to one of a pair of stereoisomers. The two isomers differ in configuration at only one stereogenic center. All other stereocenters in the molecules, if any, are the same in each. Epimerisation is a chemical process where an epimer is transformed into its chiral counterpart.

Biochemical studies have shown that the Myo Inositol (MI) stereoisomers are specifically involved in the correct activation of the insulin receptor as well as in the transduction of the message (second messenger) able to activate intracellular metabolic processes of glycolysis.

Some studies suggested that MI could play an important role in cellular morphogenesis and cytogenesis, in the synthesis of lipids, in the creation of cell membranes and in cell growth.[3],[4] It is also a precursor of phospholipids, which are responsible for the generation of important intracellular signals in mammalian oocytes and in the resumption of meiotic maturation.[5],[6],[7]

Pretreatment with MI of patients who undergo multiple follicular stimulation for IVF has become a common tool.

There is a large literature on the pre-treatment of PCOS patients and a minor literature in patients who do not have endocrine disorders

Pretratment in Patiens PCOS Undergoing IVF

The syndrome affects up to 10% of women of reproductive age, and is the most common cause of infertility in industrialized countries.[8] Its current definition requires the presence of two of the three following criteria: (1) chronic oligo-ovulation or anovulation, (2) hyperandrogenism (either clinically established or confirmed by laboratory testing); and (3) the presence of _12 follicles measuring 2–9mm in diameter in each ovary and/or increased ovarian volume (_10 ml), detected by ultrasound examination.[9] PCOS is often associated with profound insulin resistance as well with the related compensatory hyperinsulinemia. The association with hyperinsulinemia and PCOS has become clear since 1980.[10] These abnormalities, together with obesity, explain the substantially increased prevalence of glucose intolerance in PCOS.[11] Recently, the role of myo-inositol has powerfully emerged in the pathogenesis of polycystic ovary syndrome (PCOS), in particular linked with insulin resistance. In fact, some of the actions of insulin are mediated by putative inositol-containing phosphoglycan (IPG) mediators, also known as putative insulin mediators or second messengers. These mediators are generated by hydrolysis of glycosylphosphatidylinositol lipids and/or proteinated species located in the outer leaflet of the cell membrane. Two different IPG have been identified: (i) the D-chiro- IPG mediator, which activates pyruvate dehydrogenase phosphatase, and (ii) the MYO-IPG which inhibits cyclic AMP-dependent protein kinase.[12],[13] A positive role of myo-inositol in insulin-resistant women with PCOS could depend on defects in the insulin IPG-mediated signaling pathway, that seems to be primarily implicated in the pathogenesis of insulin resistance in this clinical setting.[14],[15] Accordingly, MI has been classified as an insulin sensitizing agent and it is commonly used in PCOS treatment.[16],[17],[18] By rescuing the ovarian response to endogenous gonadotropins, myo-inositol reduces perandrogenemia and reestablishes menstrual cyclicity and ovulation, increasing the chance of a spontaneous pregnancy.[19],[20] Its use in human is safe and only the highest dose (12 g/day) induced mild gastrointestinal side effects such as nausea, flatus and diarrhea.[21]

Some authors tested the effect of myo-inositol in IVF protocols with PCOS patients. Pretreatment with inositol had a variable duration: from beginning of pretreatment with GnRH analogue[22],[23],[24]up to 3 months of pre-treatment.[25],[26] These authors agree in reporting an increased recovery of Met II oocytes, a decreased use of IU FSH to reach follicular maturity. They also report a positive trend in pregnancy rate and in implantetion rate.

Has been also demonstrated[27] that myo-inositol is effective in preventing OHSS, similar to metformin; administration of myo-inositol prior to IVF treatment may favor the control of ovulation induction.

Pretreatment in Patients Non-PCOS Undergoing IVF

The literature on the pre-treatment in patients not - PCOS is not so extensive compared to the literature of pretreatment in PCOS patients. Has been observed[28] that higher concentration of MI and E2 in human follicular fluid appear to play a role in follicular maturity and can be considered a reliable marker of good quality oocytes; the mean concentration of MI was found higher in follicular fluid containing oocytes that developped into embryos with good morphology. Again same authors[29] suggest that MI may affect meiotic progression of mouse GV oocytes possibly by enhancing the intracellular Ca2+ oscillations. Supplementation of MI in culture medium may be useful for human oocyte maturation. We[30] also studied the effect of pretreatment with 4000 mg/die of inositol and 400μg of folic acid in normoovulatory patients aged <40 years and with basal FSH <10 mUI/ml undergoing multiple follicular stimulation after dowregulation with triptorelin acetate for IVF. Our findings suggested that the addition of myo-inositol to folic acid in non PCOS-patients undergoing multiple follicular stimulation for in-vitro fertilization may reduce the numbers of mature oocytes and the dosage of rFSH required to achieve follicular maturity whilst maintaining clinical pregnancy rate. Further, a trend in favor of increased incidence of implantation in the group pretreated with myo-inositol was apparent in this study. More recently[31] were compared 38 patients pretreated with MI (4 g) + folic acid (FA) (400 μg) for the previous 3 months before the enrollment day with 38 patients assuming FA (400 μg) alone; in this study patients pretreated with MI needed a total rec-FSH units significantly lower to reach follicular maturation and M2 oocytes rate was significantly higer suggesting a MI role in improving ovarian response to gonadotropins.



 
  References Top

1.
Kane MT: The effects of water-soluble vitamins on the expansion of rabbit blastocysts in vitro. J Exp Zool 1988, 245:220–223.  Back to cited text no. 1
    
2.
Brusco GF, Mariani M. Inositol: effects on oocyte quality in patients undergoing ICSI. An open study. Eur Rev Med Pharmacol Sci. 2013 Nov;17(22):3095–102.  Back to cited text no. 2
    
3.
Berridge MJ: Inositol lipids and cell proliferation. Biochim Biophys Acta 1987; 907:33–45.  Back to cited text no. 3
    
4.
Downes CP: Twenty-fifth Colworth medal lecture. The cellular functions of myo-inositol. Biochem Soc Trans 1989; 17:259–268.  Back to cited text no. 4
    
5.
Akiba S, Sato T: Cellular function of calcium-independent phospholipase A2. Biol Pharm Bull 2004; 27:1174–1178.  Back to cited text no. 5
    
6.
Aouameur R, Da Cal S, Bissonnette P, Coady MJ, Lapointe JY: SMIT2 mediates all myo-inositol uptake in apical membranes of rat small intestine. Am J Physiol Gastrointest Liver Physiol 2007; 293:G1300–1307.  Back to cited text no. 6
    
7.
Smith SD, Mikkelsen A, Lindenberg S: Development of human oocytes matured in vitro for 28 or 36 hours. Fertil Steril 2000; 73:541–544.  Back to cited text no. 7
    
8.
Nestler JE, Unfer V. Reflections on inositol(s) for PCOS therapy: steps toward success. Gynecol Endocrinol. 2015 Jul;31(7):501–5. doi: 10.3109/09513590.2015.1054802. Epub 2015 Jul 15.  Back to cited text no. 8
    
9.
Koivunen R, Laatikainen T, Tomás C, Huhtaniemi I, Tapanainen J, Martikainen H.The prevalence of polycystic ovaries in healthy women. Acta Obstet Gynecol Scand. 1999 Feb;78(2):137–41.  Back to cited text no. 9
    
10.
Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980; 50: 113–116.  Back to cited text no. 10
[PUBMED]    
11.
Dunaif A.Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997 Dec;18(6):774–800.  Back to cited text no. 11
    
12.
Larner J: Mediators of postreceptor action of insulin. Am J Med 1983; 74:38–51.  Back to cited text no. 12
    
13.
Saltiel AR: Second messengers of insulin action. Diabetes Care 1990; 13:244–256.  Back to cited text no. 13
    
14.
Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G: Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999; 340:1314–1320.  Back to cited text no. 14
    
15.
Cheang KI, Baillargeon JP, Essah PA, Ostlund RE Jr, Apridonize T, Islam L, Nestler JE: Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome. Metabolism 2008; 57:1390–1397.  Back to cited text no. 15
    
16.
Azziz R: PCOS: a diagnostic challenge. Reprod Biomed Online 2004; 8:644–648.  Back to cited text no. 16
    
17.
Baillargeon JP, Iuorno MJ, Nestler JE: Insulin sensitizers for polycystic ovary syndrome. Clin Obstet Gynecol 2003; 46:325–340.  Back to cited text no. 17
    
18.
Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE Jr, Apridonidze T, Iuorno MJ, Nestler JE: Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care 2006; 29:300–305.  Back to cited text no. 18
    
19.
Iuorno MJ, Jakubowicz DJ, Baillargeon JP, Dillon P, Gunn RD, Allan G, Nestler JE: Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract 2002; 8:417–423.  Back to cited text no. 19
    
20.
20. Unfer V, Carlomagno G, Dante G, Facchinetti F: Effects of myo- inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol 2012; 28(7):509–515.  Back to cited text no. 20
    
21.
Carlomagno G, Unfer V: Inositol safety: clinical evidences. Eur Rev Med Pharmacol Sci, 2011;15:931–936.  Back to cited text no. 21
    
22.
Pacchiarotti A(1), Carlomagno G(2), Antonini G(1,)(3), Pacchiarotti A(1,)(3). Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome. Gynecol Endocrinol. 2015 Oct; 28:1–5.  Back to cited text no. 22
    
23.
Rizzo P(1), Raffone E, Benedetto V. Effect of the treatment with myo-inositol plus folic acid plus melatonin in comparison with a treatment with myo-inositol plus folic acid on oocyte quality and pregnancy outcome in IVF cycles. A prospective, clinical trial. Eur Rev Med Pharmacol Sci. 2010 Jun;14(6):555–61.  Back to cited text no. 23
    
24.
Papaleo E(1), Unfer V, Baillargeon JP, Fusi F, Occhi F, De Santis L. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril. 2009 May;91(5):1750–4. doi: 10.1016/j.fertnstert.2008.01.088. Epub 2008 May 7.  Back to cited text no. 24
    
25.
Unfer V(1), Raffone E, Rizzo P, Buffo S. Effect of a supplementation with myo-inositol plus melatonin on oocyte quality in women who failed to conceive in previous in vitro fertilization cycles for poor oocyte quality: a prospective, longitudinal, cohort study. Gynecol Endocrinol. 2011 Nov;27(11):857–61. doi: 10.3109/09513590.2011.564687.Epub 2011 Apr 5  Back to cited text no. 25
    
26.
Ciotta L(1), Stracquadanio M, Pagano I, Carbonaro A, Palumbo M, Gulino F Effects of myo-inositol supplementation on oocyte's quality in PCOS patients: a double blind trial. Eur Rev Med Pharmacol Sci. 2011 May;15(5):509–14.  Back to cited text no. 26
    
27.
Turan GA(1), Eskicioglu F(2), Sivrikoz ON(3), Cengiz H(4,)(5), Adakan S(6), Gur EB(6), Tatar S(6), Sahin N(6), Yilmaz O(7). Myo-inositol is a promising treatment for the prevention of ovarian hyperstimulation syndrome (OHSS): an animal study. Arch Gynecol Obstet. 2015 Nov;292(5):1163–71. doi: 10.1007/s00404-015-3747-5. Epub 2015 May 20.  Back to cited text no. 27
    
28.
Chiu TT, Rogers MS, Law EL, Briton-Jones CM, Cheung LP, Haines CJ. Follicular fluid and serum concentrations of myo- inositol in patients undergoing IVF: relationship with oocyte quality. Hum Reprod. 2002 Jun;17(6):1591–6.  Back to cited text no. 28
    
29.
Chiu TT, Rogers MS, Briton-Jones C, Haines C. Effects of myo- inositol on the in-vitro maturation and subsequent development of mouse oocytes. Hum Reprod. 2003 Feb;18(2):408–16.  Back to cited text no. 29
    
30.
Lisi F, Carfagna P, Oliva MM, Rago R, Lisi R, Poverini R, Manna C, Vaquero E, Caserta D, Raparelli V, Marci R, Moscarini M. Pretreatment with myo-inositol in non polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: a pilot study. Reprod Biol Endocrinol. 2012 Jul 23;10:52. doi: 10.1186/14777827-10-52.  Back to cited text no. 30
    
31.
Caprio F, D’Eufemia MD, Trotta C, Campitiello MR, Ianniello R, Mele D, Colacurci N. Myo-inositol therapy for poor-responders during IVF: a prospective controlled observational trial. J Ovarian Res. 2015 Jun 12;8(1):37. doi: 10.1186/s13048-015-0167-x.  Back to cited text no. 31
    



This article has been cited by
1 Inositol for subfertile women with polycystic ovary syndrome
Marian G Showell,Rebecca Mackenzie-Proctor,Vanessa Jordan,Ruth Hodgson,Cindy Farquhar
Cochrane Database of Systematic Reviews. 2018;
[Pubmed] | [DOI]
2 Inositol for subfertile women with polycystic ovary syndrome
Marian G Showell,Rebecca Mackenzie-Proctor,Vanessa Jordan,Ruth Hodgson,Julie Brown,Cindy Farquhar
Cochrane Database of Systematic Reviews. 2016;
[Pubmed] | [DOI]



 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References

 Article Access Statistics
    Viewed1026    
    Printed31    
    Emailed0    
    PDF Downloaded87    
    Comments [Add]    
    Cited by others 2    

Recommend this journal